New Janus 019 _VERIFIED_

This website contains general information only and does not take account of your individual objectives, financial situation or needs. Before acting on this information you should consider the appropriateness of the information having regard to your objectives, financial situation and needs. If applicable, prospective investors should obtain a copy of the Fund's offer document, available at www.janushenderson.com/australia, and read it before making a decision about whether to invest in the Fund. Target Market Determinations for funds issued by Janus Henderson are available here: www.janushenderson.com/TMD. Prospective investors should not rely on this information and should make their own enquiries and evaluations they consider to be appropriate to determine the suitability of any investment and should seek all necessary financial, legal, tax and investment advice.

New Janus 019

If you are registering for the first time, please click on 'New to Janus Henderson Portfolio Online? Register here' below. If you have already registered, please log on by entering the email address and password that you created during registration. If you need any assistance to register or login, please contact Client Services on 1300 019 633 or +61 3 9445 5067 (outside Australia), or email clientservices.aus@janushenderson.com.

Ruxolitinib is a highly potent janus kinase inhibitor that places its users at risk for various bacterial infections and viral reactivation. However new reports are also emerging that suggest greater immunosuppression and risk for fungal disease.

This case draws attention to the degree of immunosuppression that may be seen with this drug and the need for heightened vigilance for opportunistic infections in those treated with inhibitors of janus kinase/signal transducers and activators of transcription (JAK/STAT) such as ruxolitinib. 041b061a72